Peter Wöckinger
Dados Biográficos
| ID | 10039950 |
|---|---|
| NOME | Peter Wöckinger |
| PRENOMES | Peter |
| SOBRENOME | Wöckinger |
| ASSINATURA | WÖCKINGER P |
| AFILIAÇÕES | Innsbruck Medical University |
| VERIFICADO | Não |
| TOTAL DE OBRAS | 1 |
| TOTAL DE CITAÇÕES | 0 |
| TOTAL COMO AUTOR | 1 |
| TOTAL COMO EDITOR | 0 |
| PRIMEIRO ANO DE PUBLICAÇÃO | 2025 |
| ANO MAIS RECENTE DE PUBLICAÇÃO | 2025 |
| ÍNDICE H | 0 |
Acceptance and impact of Nirsevimab and the RSVpreF vaccine following implementation in Austria
Background Since summer 2024, passive immunization with nirsevimab (Beyfortus ® ) has been recommended for all infants in Austria to prevent severe respiratory syncytial virus (RSV) infection. Maternal vaccination with RSVpreF (Abrysvo ® ), which provides transplacental protection, became available in autumn 2023. The expected public health benefits of these preventive strategies depend largely on widespread acceptance; however, real-world data f…
Sem obras proeminentes nesta página.
Acceptance and impact of Nirsevimab and the RSVpreF vaccine following implementation in Austria
Background Since summer 2024, passive immunization with nirsevimab (Beyfortus ® ) has been recommended for all infants in Austria to prevent severe respiratory syncytial virus (RSV) infection. Maternal vaccination with RSVpreF (Abrysvo ® ), which provides transplacental protection, became available in autumn 2023. The expected public health benefits of these preventive strategies depend largely on widespread acceptance; however, real-world data f…
COVID-19 Impact on Reproduction (1 obras) · Immunization (1 obras) · Immunization program (1 obras) · Parvovirus B19 Infection Studies (1 obras) · Population (1 obras) · Public health (1 obras) · Respiratory viral infections research (1 obras) · Vaccination (1 obras) · Vaccine-preventable diseases (1 obras)